Clinical trials: Tumor Pancreas
Pancreatic Cancer
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between…
- Trial name
- NCT01580241
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00089024
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Nebraska
Surgical Site Infection
Efficacy of NPWT in Reducing the Incidence of Wound Infection After Pancreatic Surgery
A disposable negative wound pressure device will be compared to standard sterile wound dressing in reducing the rate of wound infection after clean-contaminated surgical procedures on biliary tract and pancreas in patients at…
- Trial name
- NCT03700086
- Testing
- Disposable negative wound pressure device (PICO), OPsite post-op visible standard sterile dressing
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Pancreatic Cancer
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.
- Trial name
- NCT03704662
- Testing
- Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Medical College of Wisconsin
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01835041
- Testing
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00075686
- Testing
- cetuximab, gemcitabine hydrochloride
- Where
- 389 sites in United States, Canada
- Volunteers
- 766 people
- Sponsor
- SWOG Cancer Research Network
Advanced Pancreatic Cancer
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma.
- Trial name
- NCT04643405
- Testing
- APG-1387 for Injection, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Ascentage Pharma Group Inc.
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Pain, Cancer
Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Management of Pain in Abdominal Non-pancreatic Malignancies
Celiac plexus neurolysis (CPN) has been performed for nearly 100 years to alleviate the abdominal pain associated with pancreatic malignancy and other conditions, and is usually undertaken at a late stage in the disease process…
- Trial name
- NCT01166529
- Testing
- EUS-guided Celiac Plexus Neurolysis
- Where
- United States
- Sponsor
- Northwestern University
Melanoma, Breast Cancer
Safety Study of Modified Vaccinia Virus to Cancer
The purpose of this study is to determine the safety and maximum tolerated dose from injecting this vaccinia virus into tumors or infusion.
- Conditions
- Melanoma, Breast Cancer, Head and Neck Squamous Cell Cancer, Liver Cancer
- Trial name
- NCT00574977
- Testing
- Vaccinia virus (vvDD-CDSR)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- David Bartlett
Advanced Pancreatic Cancer
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected…
- Trial name
- NCT01303172
- Testing
- IMM-101, Gemcitabine
- Where
- 21 sites in Cyprus, Ireland and 3 more
- Volunteers
- 110 people
- Sponsor
- Immodulon Therapeutics Ltd
Refractory Neoplasms
Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas
The pupose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess…
- Trial name
- NCT02822066
- Testing
- Electroporation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Pancreatic Cancer
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
- Trial name
- NCT00614653
- Testing
- Bevacizumab, Erlotinib, Capecitabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- LOTUS (NCT06073431)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 225 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Rochester
Pancreatic Cancer, Hypoxia
A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer
This is a diagnostic study to look for low levels of oxygen (hypoxia) in pancreatic cancer using an imaging test called positron emission tomography (PET).
- Trial name
- NCT01542177
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01327794
- Testing
- polymorphism analysis, immunologic technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastrinoma, Glucagonoma
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00075439
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib).
- Trial name
- NCT01431794
- Testing
- LDE225-600mg, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer
A Multi-center Study on the Efficacy and Safety of AI-assisted Navigation System for Biliopancreatic EUS
Pancreatic cancer is one of the most lethal cancers. Survival rates vary largely depending on the stage at which it is diagnosed. EUS is considered one of the most sensitive modalities for pancreatic cancer detection.
- Trial name
- NCT04892329
- Testing
- Artificial intelligence assistant system
- Where
- 2 sites in China
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.